Stockreport

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker [Yahoo! Fina...

Alto Neuroscience, Inc.  (ANRO) 
PDF MOUNTAIN VIEW, Calif., February 19, 2025 BUSINESS WIRE )--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the develo [Read more]